These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 21766666)

  • 21. Primary aldosteronism: the most frequent form of secondary hypertension?
    Shargorodsky M; Zimlichman R
    Isr Med Assoc J; 2002 Jan; 4(1):32-3. PubMed ID: 11802308
    [No Abstract]   [Full Text] [Related]  

  • 22. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antihypertensive drugs].
    Peters G; Peters-Haefeli L
    Rev Med Suisse Romande; 1974 Aug; 94(8):589-614. PubMed ID: 4373810
    [No Abstract]   [Full Text] [Related]  

  • 24. [Anti-hypertensive treatment in metabolic syndrome--focus on ARB or ACE inhibitor].
    Yano Y; Kario K
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():576-81. PubMed ID: 21766663
    [No Abstract]   [Full Text] [Related]  

  • 25. First orally active DRI Aliskiren--a new prospect in management of hypertension and beyond.
    Sawhney JP
    Indian Heart J; 2010; 62(1):49-56. PubMed ID: 21180035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients?
    Gaddam KK; Oparil S
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):484-90. PubMed ID: 18695389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S; Bernheim J; Podjarny E
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of aldosterone antagonists in resistant hypertension.
    Calhoun DA
    Prog Cardiovasc Dis; 2006; 48(6):387-96. PubMed ID: 16714158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Alpha inhibitor].
    Ishigami T; Totani Y; Umemura S
    Nihon Rinsho; 2006 Dec; 64 Suppl 9():611-7. PubMed ID: 17458291
    [No Abstract]   [Full Text] [Related]  

  • 30. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study.
    Giacchetti G; Ronconi V; Turchi F; Agostinelli L; Mantero F; Rilli S; Boscaro M
    J Hypertens; 2007 Jan; 25(1):177-86. PubMed ID: 17143190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recent advances in hypertension therapy (author's transl)].
    Würsten D; Siegenthaler G; Siegenthaler W; Nussberger J; Schmied U; Beckerhoff R; Vetter W
    Schweiz Rundsch Med Prax; 1975 Apr; 64(13):373-82. PubMed ID: 2907
    [No Abstract]   [Full Text] [Related]  

  • 32. Hypertensive treatment in patients with metabolic syndrome.
    Siegel D; Swislocki AL
    Metab Syndr Relat Disord; 2010 Apr; 8(2):95-104. PubMed ID: 20156078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldosterone and cardiovascular disease.
    Gaddam KK; Pimenta E; Husain S; Calhoun DA
    Curr Probl Cardiol; 2009 Feb; 34(2):51-84. PubMed ID: 19135616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Normokalemic primary hyperaldosteronism].
    Vonend O; Rump LC
    Dtsch Med Wochenschr; 2006 Nov; 131(46 Spec No):H24-7. PubMed ID: 17109245
    [No Abstract]   [Full Text] [Related]  

  • 35. [Aldosterone blockade in essential hypertension].
    Venco A; Grandi AM
    Ital Heart J; 2005 May; 6 Suppl 1():34S-42S. PubMed ID: 15945298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New findings with RAS inhibitors in diabetic nephropathy].
    Ito S
    Nihon Jinzo Gakkai Shi; 2007; 49(5):485-90. PubMed ID: 17695809
    [No Abstract]   [Full Text] [Related]  

  • 37. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
    Turgut F; Balogun RA; Abdel-Rahman EM
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A symposium: International update--the important role of aldosterone and aldosterone antagonism in cardiovascular medicine. Based on symposia held in Brussels, Belgium and Newport Beach, California.
    Am J Cardiol; 1990 Jun; 65(23):1K-57K. PubMed ID: 2353664
    [No Abstract]   [Full Text] [Related]  

  • 39. [Aldosterone antagonists and a direct renin inhibitor in the treatment of the metabolic syndrome].
    Tamura N; Nakao K
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():592-6. PubMed ID: 21766666
    [No Abstract]   [Full Text] [Related]  

  • 40. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome.
    Schrier RW; Masoumi A; Elhassan E
    Clin J Am Soc Nephrol; 2010 Jun; 5(6):1132-40. PubMed ID: 20448074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.